LA Financiere DE L Echiquier Acquires 26,891 Shares of Edwards Lifesciences Co. (NYSE:EW)

LA Financiere DE L Echiquier grew its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 446,973 shares of the medical research company's stock after acquiring an additional 26,891 shares during the period. Edwards Lifesciences accounts for 1.6% of LA Financiere DE L Echiquier's portfolio, making the stock its 21st largest holding. LA Financiere DE L Echiquier owned about 0.07% of Edwards Lifesciences worth $34,082,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Castleview Partners LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $25,000. Compass Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $31,000. Jackson Grant Investment Advisers Inc. acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $38,000. Janiczek Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company's stock valued at $40,000 after purchasing an additional 303 shares in the last quarter. Finally, Sunbelt Securities Inc. acquired a new stake in Edwards Lifesciences during the 1st quarter worth $49,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

EW traded down $0.30 on Monday, reaching $92.40. The company had a trading volume of 2,667,004 shares, compared to its average volume of 3,989,706. The company's fifty day moving average is $89.03 and its 200 day moving average is $77.18. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The stock has a market cap of $55.62 billion, a P/E ratio of 40.17, a P/E/G ratio of 4.59 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the prior year, the business posted $0.64 EPS. The business's revenue was up 13.3% compared to the same quarter last year. As a group, analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of analyst reports. Oppenheimer lifted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a report on Monday, March 18th. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a report on Thursday, March 7th. Wells Fargo & Company raised shares of Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 price target for the company in a report on Friday, February 2nd. Truist Financial boosted their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, December 22nd. Finally, Evercore ISI boosted their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an "in-line" rating in a report on Thursday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $90.67.

Insider Transactions at Edwards Lifesciences

In related news, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company's stock, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, VP Catherine M. Szyman sold 27,000 shares of the firm's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company's stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of the firm's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now directly owns 4,486 shares of the company's stock, valued at approximately $388,801.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 204,004 shares of company stock valued at $17,922,954. Company insiders own 1.27% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.